A third vaccine against Corona ... America allows the use of the Johnson & Johnson vaccine with a single dose

The single-dose vaccine, developed by Johnson & Johnson, of the American company, has obtained official approval from US regulators, making it the third available vaccine in the United States.

The vaccine was given the green light a day after a panel of independent experts delivered its approval to the US Food and Drug Administration.

President Joe Biden described the licensing as an "encouraging development," and said it followed a "rigorous, open and objective scientific review process."

"We know that the more people are vaccinated, the faster we can overcome the virus and return to our friends and loved ones, and put our economy back on track," Biden said in a statement.

But he also warned that things were still likely to get worse with the spread of new strains, and urged Americans to continue washing their hands, using masks and maintaining social distancing.

For her part, Janet Woodcock, Acting Commissioner of Administration, said - in a statement - that the licensing of this vaccine expands the availability of vaccines, which helps fight this epidemic that has killed more than half a million people in the United States.

Clear evidence

In a related context, the US Food and Drug Administration, referring to the vaccine bearing the name of the Johnson & Johnson company, Jansen, said - in a statement on Saturday - that there is "clear evidence" that it may be effective in preventing Covid-19, Confirming that it will be distributed in the United States for use among individuals aged 18 years and over.

New Jersey-based Johnson & Johnson said 20 million doses will be delivered in the United States by the end of March, and the company plans to provide 100 million doses during the first half of 2021.

Doses can be stored in a regular refrigerator, unlike in the extremely cold conditions required by the other two vaccines produced by Moderna and Pfizer-BioNTech, which are both two-dose regimens.

And a global clinical experience showed that the Johnson & Johnson vaccine was 66% effective in preventing various variants of the Corona virus, and was 85% effective in protecting against severe cases.

It is reported that the total number of deaths related to the Corona virus exceeded 500,000 people in the United States last week, according to data compiled by Johns Hopkins University.